Following an abandoned collaboration agreement between a complex peptide formulator and a generic manufacturer, CRA was retained to support an academic senior consultant in the ensuing arbitration. CRA’s team examined lost profit damages for the formulator, examining uptake and pricing of the specialty drug with an orphan drug indication. The matter ultimately settled.
2024 International Arbitration review: Updates and trends
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...